Virtual Graffiti is a Irvine, CA-based company in the Computers and Electronics sector.
We are transforming the way people and teams communicate using the power of their voice. Our platform delivers secure, real-time voice communication across a constellation of connected devices, applications, and services. We give mobile teams a heads-up, eyes-free experience that enables them to communicate without losing focus, across any distance, anywhere in the world. Our products include Onyx, the award-winning connected voice wearable for teams that helps teams communicate across any distance, and Orion Pro service, which gives organizations control and flexibility to manage real-time communication. We recently announced a preview of our first voice bot: Orion Translator, for real-time voice translation, initially available for Onyx in English to Spanish/Spanish to English. The newest addition to our constellation of connected devices is Orion Sync, a ground-breaking, LTE-enabled push-to-talk wearable that continues our mission of providing teams with real-time, heads-up communication at the push of a button. Orion was founded by cloud infrastructure pioneers Jesse Robbins and Greg Albrecht who were inspired by their experiences using traditional radios as firefighters and EMTs. Orion Labs is backed by leading investors and is based in San Francisco, CA.
Harbor Link is a Baltimore-based dark fiber provider specializing in the design, build, and maintenance of dark fiber and private networks.
N-Link Corporation is a Bellevue, WA-based company in the Computers and Electronics sector.
Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies – including many of the top 20 pharmaceutical companies – use Saama`s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial led to the world`s first COVID-19 vaccine. LSAC`s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Application (NDAs) more efficiently and bring treatments to patients sooner.